Tag Archives: biosimilars

Industry Regulatory Issues to be Highlighted at 2012 BIO International Convention

bio-session

In the words of BIO’s Andrew Emmett, Managing Director, Science & Regulatory Affairs, ‘2012 is shaping up to be a momentous year for FDA reform.’ From the reauthorization of the Prescription Drug User Fee Act (PDUFA V) to modernizing and expediting the approval of new drugs and biologics, implementing the new biosimilars pathways and addressing the growing global drug shortage crisis, all eyes are on the current regulatory environment and its role in supporting innovation. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO IP Counsels Conference Agenda Topics

bio-ip-events-btn

Join us in Austin for BIO’s Intellectual Property Counsels Committee Conference on April 16-18.  Agenda topics are below. The Decline of Process Patents: This session will examine the enforceability of process claims and how it has led to the recent controversy around divided infringement. Unlike claims to machines, manufactures, and compositions, process claims can be divided up by different actors, or by jurisdiction, and conceivably even by time.  Right now the focus is on different Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BioCentury TV at BIO International Convention

marq_080711_play

BioCentury TV interviewed biotech leaders throughout the recent BIO International Convention in Washington, DC. The first interview can be found here (links to the other interviews can be found on the right). (July 24) Public+Private Part 1 — Turning Great Science into Medicine — and Jobs: Dr. Michel Goldman of Europe’s Innovative Medicines Initiative xplains how the pharma-driven agenda is creating a new “ecosystem” in Europe for drug developers. (July 31) Public+Private Part 2 – Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biologics & Biosimilars: What is the Science Telling Us?

5161819684_322d02e59a

Panelists from the varied backgrounds of academia, business and regulation agreed on the highest scientific standards of biosimilar regulation. Each panelist emphasized the need for the most stringent of standards in order to ensure patient safety and efficacy within the emerging biosimilars market. As Brian Liang, Executive Director of the Institute of Health Law Studies at California Western School of Law, summed it up, “the need in biosimilars is to focus on science, not cost. These are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotech Patenting and Tech Transfer at 2011 BIO International Convention

BIO11_ConvLogo_L_RGB

The Biotech Patenting and Tech Transfer track has a lot to offer 2011 BIO International Convention Attendees.  High level speakers include White House Intellectual Property Enforcement Coordinator Victoria Espinel, European Patent Office Director of Biotechnology Sjoerd Hoekstra, retired Chief Judge of the U.S. Court of Appeals for the Federal Circuit Paul Michel, and former Solicitors General Seth Waxman and Paul Clement to name a few.                 I am particularly excited about the breadth of the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , ,